Lupin 2024

drug prices

New report finds drug prices have become more affordable to most patients

New report finds drug prices have become more affordable to most patients

DANBURY, Conn.— The vast majority of patients in the United States are experiencing lower out-of-pocket costs for their drugs, paying a smaller share of costs and seeing a downward trend in their costs on average. That’s according to the latest report from The IQVIA Institute for Human Data Science, Medicine Spending and Affordability in the

Pelosi unveils drug pricing plan

Pelosi unveils drug pricing plan

WASHINGTON — House Speaker Nancy Pelosi (D., Calif.) on Thursday released her long awaited plan to lower drug prices for seniors on Medicare and younger people with private insurance. The proposal would allow Medicare to negotiate prices for up to 250 of the costliest drugs, including insulin. Drug manufacturers balking at negotiations would face harsh

Value-based contracts provide promise and potential

Value-based contracts provide promise and potential

There has been significant focus and attention paid to the issue of drug prices in the last few years. As Adam Fein, president of Pembroke Consulting Inc. and chief executive officer of Drug Channels Institute, has said, “Drugs are 12% of the costs, but 90% of the ­conversation.” Fortunately, the spirited national conversation about drug

Prices boosted on hundreds of drugs

Prices boosted on hundreds of drugs

NEW YORK — Drugmakers are increasing the price of hundreds of drugs by an average of more than 6%, according to a new analysis by Rx Savings Solutions. With pressure on the pharmaceutical industry to hold down prices mounting, many of the increases are relatively small. But some generics are seeing steep hikes, and overall

Industry gives president’s plan warm welcome

Industry gives president’s plan warm welcome

NEW YORK — Chain drug retailers reacted favorably to President Trump’s drug price cutting plan; branded pharmaceutical manufacturers less so. Walgreens, which had pharmacists at the White House for the president’s announcement of the proposal, said in a statement the blueprint “is a positive step forward in addressing the issue of rising drug prices.” The

FDA acts to boost Rx drug competition

FDA acts to boost Rx drug competition

WASHINGTON — The Food and Drug Administration today announced two new steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the first time, a new policy to expedite the review of

Senators launch investigation of Rx pricing

Senators launch investigation of Rx pricing

WASHINGTON — A U.S. Senate committee has begun a probe of recent spikes in pharmaceutical pricing. Sens. Susan Collins (R., Maine) and Claire McCaskill (D., Mo.), who lead the Senate Special Committee on Aging, on Wednesday said the bipartisan investigation will include hearings, with the first slated for next month. The lawmakers noted that the

Centrum 7/6  banner